New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
With September marking the kickoff of the pro-football season and National Prostate Cancer Awareness Month, the Urology Care Foundation and the National Football League (NFL) teamed up to release a new Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to join the Know Your Stats® campaign.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63352-nfl-and-urology-care-foundation-national-prostate-cancer-awareness-month
Experience prostate-centered orgasms with this flexible silicone massager! Its contoured head is shaped to slide in comfortably when lubed and stays right where you need it. A perfectly placed textured nub also stimulates perineum for added sensations. Just press the button and powerful vibrations for deep orgasms!
Finally, the perfectly sized prostate vibe in the perfectly safe material. Its round head always hits the spot and the flexible body that is ideally shaped to surround the perineum with gentle vibration. Powerful waterproof bullet included. Truly the best among prostate massagers.
Professor Puppet After Dark is brought to you by Adam & Eve. Go now to http://AdamAndEve.com and enter the Adam & Eve Coupon Code HANS to enjoy 50% OFF almost ANY item. Plus FREE Shipping , a FREE Special Gift, and FREE DVD’s.
Professor Hans and Penelope Lombard address an excellent viewer fan mail question from Lory this week. Will using a vibrator too often desensitize one from regular sex? There are two main results that you can get when using an electronic device or an artificial toy during solo play too often. One is that, essentially, you will get yourself numb and will crave for more powerful vibrations. Second, is that you will tend to train yourself to cum too quickly. We all know that women take a little longer to get off than men. Here’s another point though. It’s really good to have your prostate ejaculate maybe every couple of days but you just need to discipline yourself not to make it too often. Otherwise, you will lose your sexual appetite.
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
With the kick-off of pro football season and September marking National Prostate Cancer Awareness Month, the American Urological Association (AUA) Foundation and the National Football League (NFL) have teamed up for a third year to educate men about prostate health and encourage them to join the “Know Your Stats” campaign. With the support of an increasing number of NFL greats and prostate cancer survivors, the national campaign is focused on turning awareness into action by encouraging men to know their risks and get tested.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51874-aua-foundation-nfl-mike-haynes-know-your-stats-prostate-cancer-awareness
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Legacy®, through an unrestricted educational grant from Genentech, launches two new resources devoted to helping smokers understand their risks for lung cancer and reducing their risks for mortality.
Lung cancer is the nation's number one cancer killer of both men and women, accounting for 28 percent of all cancer deaths. More Americans are killed by lung cancer than by breast cancer, prostate cancer, or any other cancer. Up to 90 percent of lung cancer cases result from smoking and no current treatment can cure lung cancer. Early detection is the key to better quality and longevity of life.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/legacy/47244/
Based on its recent analysis of the prostate cancer diagnosis market, Frost & Sullivan recognizes Hybridyne Technologies, Inc. with the 2010 North American Frost & Sullivan Award for Technology Innovation of the Year.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/47727/
